EOM 1352: Fri 7 June 2024, 11:36

Current Edition

Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Europe

Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that pa...
Continue Reading →
Europe

Gene-targeted cancer drugs, slow release overcome resistance

Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering...
Continue Reading →
Europe

SMi’s 9th Annual Orphan Drugs & Rare Diseases Conference

15 - 16 October 2019, London, UK.The orphan drug market is continuously growing and is expected to reach $176 billion by 2020, with a CGR of 10.5% just for orphan dr...
Continue Reading →
Europe

Clinerion partners with Volv Global to bring treatment earlier to patients by enhancing diagnosis search on Patient Network Explorer with inTrigue AI algorithms 

ꟷ     Volv Global’s inTrigue AI algorithms identify diagnostic signals from patient medical record data and help patients receive treatment earlier by enabling earl...
Continue Reading →
Europe

J&J scores Spravato trial win in high-risk depression. Will doctors and payers buy in?

Johnson & Johnson is attempting to change the antidepression market with its ketamine-derivative Spravato despite strict dosing requirements and a steep list pri...
Continue Reading →
Europe

Sandoz announces global deal to commercialize proposed biosimilar natalizumab, a key multiple sclerosis medicine

Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into a global commercialization agreement for a proposed natalizumab bi...
Continue Reading →
Europe

Boehringer Ingelheim eExpands KRAS cancer program with Lupin’s clinical stage MEK inhibitor compound

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a ...
Continue Reading →
Europe

AstraZeneca aims to pump up Farxiga marketing after cardio outcomes study

Now that AstraZeneca has scored its Farxiga outcomes data, it's aiming to change the game on its SGLT2 diabetes rivals. First up? Expanding its salesforce to pr...
Continue Reading →
Europe

Breast cancer can form ‘sleeper cells’ after drug treatment

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the...
Continue Reading →
Europe

We Need To Rethink What We Know About Alzheimer’s

Johnson and Johnson recently announced that it was halting a clinical trial for a new Alzheimer’s drug after safety issues emerged. This latest failure adds to the d...
Continue Reading →
Catalyst: 12th January 2026
Quotient